Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study

AC. Leeksma, P. Baliakas, T. Moysiadis, A. Puiggros, K. Plevova, AM. Van der Kevie-Kersemaekers, H. Posthuma, AE. Rodriguez-Vicente, AN. Tran, G. Barbany, L. Mansouri, R. Gunnarsson, H. Parker, E. Van den Berg, M. Bellido, Z. Davis, M. Wall, I....

. 2021 ; 106 (1) : 87-97. [pub] 20210101

Language English Country Italy

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21019540

Grant support
C34999/A18087 Cancer Research UK - United Kingdom
C24563/A15581 Cancer Research UK - United Kingdom

Complex karyotype (CK) identified by chromosome-banding analysis (CBA) has shown prognostic value in chronic lymphocytic leukemia (CLL). Genomic arrays offer high-resolution genome-wide detection of copy-number alterations (CNAs) and could therefore be well equipped to detect the presence of a CK. Current knowledge on genomic arrays in CLL is based on outcomes of single center studies, in which different cutoffs for CNA calling were used. To further determine the clinical utility of genomic arrays for CNA assessment in CLL diagnostics, we retrospectively analyzed 2293 arrays from 13 diagnostic laboratories according to established standards. CNAs were found outside regions captured by CLL FISH probes in 34% of patients, and several of them including gains of 8q, deletions of 9p and 18p (p<0.01) were linked to poor outcome after correction for multiple testing. Patients (n=972) could be divided in three distinct prognostic subgroups based on the number of CNAs. Only high genomic complexity (high-GC), defined as ≥5 CNAs emerged as an independent adverse prognosticator on multivariable analysis for time to first treatment (Hazard ratio: 2.15, 95% CI: 1.36-3.41; p=0.001) and overall survival (Hazard ratio: 2.54, 95% CI: 1.54-4.17; p<0.001; n=528). Lowering the size cutoff to 1 Mb in 647 patients did not significantly improve risk assessment. Genomic arrays detected more chromosomal abnormalities and performed at least as well in terms of risk stratification compared to simultaneous chromosome banding analysis as determined in 122 patients. Our findings highlight genomic array as an accurate tool for CLL risk stratification.

Amsterdam University Medical Centers University of Amsterdam

Amsterdam University Medical Centers University of Amsterdam The Netherlands

Amsterdam University Medical Centers Vrije Universiteit Amsterdam The Netherlands

Cancer Genomics Academic Unit of Cancer Sciences University of Southampton

Cancer Genomics Academic Unit of Cancer Sciences University of Southampton Southampton UK

CEITEC University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Cytogenetics department St Vincent Hospital Melbourne Victoria Australia

Department of Oncology Pathology Karolinska Institutet Stockholm

Department of Oncology Pathology Karolinska Institutet Stockholm Sweden

Dept of Clinical Genetics Amsterdam University Medical Centers Univ of Amsterdam The Netherlands

Dept of Experimental Oncology IRCCS Ospedale San Raffaele Università Vita Salute Milan

Dept of Genetics University Medical Center Groningen University of Groningen The Netherlands

Dept of Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Sweden

Dept of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden

Dept of Molecular Pathology Royal Bournemouth Hospital Bournemouth UK

Division of Clinical Genetics Dept of Laboratory Medicine Lund University Lund Sweden

Hematology Amsterdam University Medical Centers University of Amsterdam The Netherlands

Hospital del Mar Barcelona

IBSAL IBMCC Centro de Investigación del Cancer Universidad de Salamanca CSIC Spain

Institut Universitaire du Cancer de Toulouse Oncopole Toulouse France

Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece

Laboratori de Citogenetica Molecular Servei de Patologia Hospital del Mar Barcelona Spain

MLL Munich Leukemia Laboratory Munich Germany

Oncogenomic laboratory Dept of Hematology Lausanne University Hospital Switzerland

Radboud University Medical Center Dept of Human Genetics Nijmegen The Netherlands

Service d'Hematologie Biologique Hopital Pitié Salpetriere APHP Paris France

St Vincent Hospital Melbourne Peter MacCallum Cancer Center University of Melbourne Australia

University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

University Hospital Brno Masaryk University Brno Czech Republic

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019540
003      
CZ-PrNML
005      
20210830101130.0
007      
ta
008      
210728s2021 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2019.239947 $2 doi
035    __
$a (PubMed)31974198
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Leeksma, Alexander C $u Amsterdam University Medical Centers, University of Amsterdam
245    10
$a Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study / $c AC. Leeksma, P. Baliakas, T. Moysiadis, A. Puiggros, K. Plevova, AM. Van der Kevie-Kersemaekers, H. Posthuma, AE. Rodriguez-Vicente, AN. Tran, G. Barbany, L. Mansouri, R. Gunnarsson, H. Parker, E. Van den Berg, M. Bellido, Z. Davis, M. Wall, I. Scarpelli, A. Österborg, L. Hansson, M. Jarosova, P. Ghia, P. Poddighe, B. Espinet, S. Pospisilova, C. Tam, L. Ysebaert, F. Nguyen-Khac, D. Oscier, C. Haferlach, J. Schoumans, M. Stevens-Kroef, E. Eldering, K. Stamatopoulos, R. Rosenquist, JC. Strefford, C. Mellink, AP. Kater
520    9_
$a Complex karyotype (CK) identified by chromosome-banding analysis (CBA) has shown prognostic value in chronic lymphocytic leukemia (CLL). Genomic arrays offer high-resolution genome-wide detection of copy-number alterations (CNAs) and could therefore be well equipped to detect the presence of a CK. Current knowledge on genomic arrays in CLL is based on outcomes of single center studies, in which different cutoffs for CNA calling were used. To further determine the clinical utility of genomic arrays for CNA assessment in CLL diagnostics, we retrospectively analyzed 2293 arrays from 13 diagnostic laboratories according to established standards. CNAs were found outside regions captured by CLL FISH probes in 34% of patients, and several of them including gains of 8q, deletions of 9p and 18p (p<0.01) were linked to poor outcome after correction for multiple testing. Patients (n=972) could be divided in three distinct prognostic subgroups based on the number of CNAs. Only high genomic complexity (high-GC), defined as ≥5 CNAs emerged as an independent adverse prognosticator on multivariable analysis for time to first treatment (Hazard ratio: 2.15, 95% CI: 1.36-3.41; p=0.001) and overall survival (Hazard ratio: 2.54, 95% CI: 1.54-4.17; p<0.001; n=528). Lowering the size cutoff to 1 Mb in 647 patients did not significantly improve risk assessment. Genomic arrays detected more chromosomal abnormalities and performed at least as well in terms of risk stratification compared to simultaneous chromosome banding analysis as determined in 122 patients. Our findings highlight genomic array as an accurate tool for CLL risk stratification.
650    _2
$a chromozomální aberace $7 D002869
650    _2
$a genom lidský $7 D015894
650    _2
$a genomika $7 D023281
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x diagnóza $x genetika $7 D015451
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Baliakas, Panagiotis $u Dept of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden
700    1_
$a Moysiadis, Theodoros $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece
700    1_
$a Puiggros, Anna $u Hospital del Mar, Barcelona
700    1_
$a Plevova, Karla $u University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Van der Kevie-Kersemaekers, Anne-Marie $u Dept of Clinical Genetics, Amsterdam University Medical Centers, Univ of Amsterdam, The Netherlands
700    1_
$a Posthuma, Hidde $u Dept of Clinical Genetics, Amsterdam University Medical Centers, Univ of Amsterdam, The Netherlands
700    1_
$a Rodriguez-Vicente, Ana E $u IBSAL, IBMCC, Centro de Investigación del Cancer, Universidad de Salamanca-CSIC, Spain
700    1_
$a Tran, Anh Nhi $u Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Barbany, Gisela $u Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Mansouri, Larry $u Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Gunnarsson, Rebeqa $u Division of Clinical Genetics, Dept of Laboratory Medicine, Lund University, Lund, Sweden
700    1_
$a Parker, Helen $u Cancer Genomics, Academic Unit of Cancer Sciences, University of Southampton, Southampton, UK
700    1_
$a Van den Berg, Eva $u Dept of Genetics, University Medical Center Groningen, University of Groningen, The Netherlands
700    1_
$a Bellido, Mar $u Dept of Genetics, University Medical Center Groningen, University of Groningen, The Netherlands
700    1_
$a Davis, Zadie $u Dept of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK
700    1_
$a Wall, Meaghan $u Cytogenetics department, St Vincent Hospital Melbourne, Victoria, Australia
700    1_
$a Scarpelli, Ilaria $u Oncogenomic laboratory, Dept of Hematology, Lausanne University Hospital (CHUV), Switzerland
700    1_
$a Österborg, Anders $u Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Hansson, Lotta $u Department of Oncology-Pathology, Karolinska Institutet, Stockholm
700    1_
$a Jarosova, Marie $u University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ghia, Paolo $u Dept. of Experimental Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milan
700    1_
$a Poddighe, Pino $u Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, The Netherlands
700    1_
$a Espinet, Blanca $u Laboratori de Citogenetica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain
700    1_
$a Pospisilova, Sarka $u CEITEC, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Tam, Constantine $u St Vincent Hospital Melbourne, Peter MacCallum Cancer Center, University of Melbourne, Australia
700    1_
$a Ysebaert, Loïc $u Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
700    1_
$a Nguyen-Khac, Florence $u Service d'Hematologie Biologique, Hopital Pitié-Salpetriere, APHP, Paris, France
700    1_
$a Oscier, David $u Dept of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK
700    1_
$a Haferlach, Claudia $u MLL Munich Leukemia Laboratory, Munich, Germany
700    1_
$a Schoumans, Jacqueline $u Oncogenomic laboratory, Dept of Hematology, Lausanne University Hospital (CHUV), Switzerland
700    1_
$a Stevens-Kroef, Marian $u Radboud University Medical Center, Dept of Human Genetics, Nijmegen, The Netherlands
700    1_
$a Eldering, Eric $u Amsterdam University Medical Centers, University of Amsterdam, The Netherlands
700    1_
$a Stamatopoulos, Kostas $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece
700    1_
$a Rosenquist, Richard $u Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Strefford, Jonathan C $u Cancer Genomics, Academic Unit of Cancer Sciences, University of Southampton
700    1_
$a Mellink, Clemens $u Amsterdam University Medical Centers, University of Amsterdam, The Netherlands
700    1_
$a Kater, Arnon P $u Hematology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 106, č. 1 (2021), s. 87-97
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31974198 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101130 $b ABA008
999    __
$a ok $b bmc $g 1690382 $s 1139986
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 106 $c 1 $d 87-97 $e 20210101 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a C34999/A18087 $p Cancer Research UK $2 United Kingdom
GRA    __
$a C24563/A15581 $p Cancer Research UK $2 United Kingdom
LZP    __
$a Pubmed-20210728
Back

Find record

Citation metrics

Archiving options